SITUATION 02
We have research, but no real commercial evidence
Knowing a market is not the same as knowing how the market will respond to you.
A company can understand market size, competitors, regulations, channels and customer profiles — and still have very little evidence about whether the right accounts will engage, what decision-makers will challenge, or whether opportunities can actually progress.
Research creates context.
Commercial evidence changes decisions.
WHY THIS MATTERS
Research is useful when it improves the questions.
It becomes dangerous when it is mistaken for validation.
A well-researched market can still produce:
- weak account response
- poor access to decision-makers
- repeated objections
- limited urgency
- a mismatch between the offer and buyer priorities
- pricing or delivery constraints
- partner enthusiasm without customer traction
The risk is not having too little information.
The risk is making a commercial commitment based on information that has never been tested against real market behavior.
WHAT IS USUALLY MISSING
Companies in this situation often already have:
- market reports
- competitor analysis
- market-size estimates
- channel maps
- internal strategy work
- distributor discussions
- buyer personas
- regulatory or sector information
What remains uncertain is commercial reality.
That means:
- which accounts deserve priority
- which decision-makers will engage
- which messages create interest
- which objections repeat
- what the buyer actually values
- whether access is credible
- whether initial interest progresses
- what blocks movement
- what the market is asking the company to change
HOW VIAPORA TREATS THE DOSSIER
VIAPORA does not discard existing research.
We convert it into testable commercial hypotheses.
The dossier is structured around:
- what is already believed to be true
- what is supported by external information
- what remains an assumption
- what must be tested commercially
- which accounts can provide the strongest evidence
- which decision-makers matter
- what signals would support, weaken or change the thesis
From there, VIAPORA prioritizes the account universe, defines access logic and moves into real commercial interaction.
The purpose is to confront the existing analysis with buyer response.
Outreach, conversations, qualification, follow-up and opportunity movement reveal where the research is useful, incomplete or misleading.
Research informs the starting point.
The market decides what survives contact.
KNOWN / ASSUMED / OBSERVED / ACTIONABLE
A strong dossier should help leadership distinguish:
KNOWN
What is already supported by credible information.
ASSUMED
What has not yet been commercially tested.
OBSERVED
What real accounts and decision-makers are showing.
ACTIONABLE
What should change because of the evidence.
This distinction is central to VIAPORA's method.
It prevents analysis from becoming certainty before the market has spoken.
WHAT COMMERCIAL EVIDENCE LOOKS LIKE
Commercial evidence can include:
- real response from priority accounts
- access to relevant decision-makers
- repeated buyer questions
- recurring objections
- buyer language and priorities
- meetings that progress into next actions
- qualified opportunity signals
- blockers that persist across accounts
- changes in the perceived value proposition
- evidence that a segment should be prioritized or deprioritized
Not every interaction is evidence of traction.
The value comes from patterns, progression and context.
WHAT THE CLIENT STILL OWNS
VIAPORA can test commercial assumptions.
The client remains responsible for:
- technical truth
- product capability
- pricing authority
- delivery feasibility
- contractual commitments
- final implementation and delivery
The client also needs to react when live market evidence challenges an internal assumption.
Evidence only creates value if the organization is prepared to use it.
LIKELY MANDATE PATH
ME90 is the primary mandate for this situation.
The purpose is not to redo the research.
It is to convert existing knowledge into commercial testing.
The mandate moves the dossier from: research → hypotheses → priority accounts → access → live commercial response → evidence → decision.
The possible conclusion may be:
- the research was directionally correct
- the market is attractive, but the ICP needs adjustment
- the access route is wrong
- the offer framing needs revision
- buyer urgency is lower than expected
- the market does not currently justify further commitment
WHEN VIAPORA MAY NOT BE THE RIGHT FIT
VIAPORA may not be the right fit when:
- the company only wants another market study
- leadership is not ready for external commercial interaction
- the offer cannot yet be discussed credibly with buyers
- no internal owner can respond to technical, pricing or delivery questions
- the company is unwilling to revise its assumptions when the market contradicts them
The market must have a chance to disagree
Good research should make the company better prepared.
It should not make the company less willing to learn.
The most useful validation begins when the market is allowed to challenge the internal thesis.
If your company has done the research but still lacks real commercial evidence, discuss the dossier with VIAPORA.